Insmed Appoints Myrtle Potter to its Board of Directors
15 Décembre 2014 - 2:00PM
Business Wire
Pharmaceutical executive brings 30 years of
commercial and operations leadership
Insmed Incorporated (Nasdaq:INSM) today
announced the appointment of Myrtle Potter to its Board of
Directors. Ms. Potter is currently CEO of Myrtle Potter &
Company, a life sciences and healthcare advisory firm she founded
in 2005. She was previously the President of Commercial Operations
and Chief Operating Officer of Genentech and had extensive
experience in senior operating roles at Bristol-Myers Squibb and
Merck.
“It is with great pleasure that we welcome
Myrtle to our Board. Her considerable industry experience, deep
insight into successful commercialization strategies and experience
leading pharmaceutical companies in bringing new therapies to
market will be extremely valuable to Insmed as we prepare for the
commercialization of ARIKAYCETM,” stated Don Hayden, Jr., Chairman
of the Board of Insmed.
In accepting this appointment, Ms. Potter
stated, “I am excited to join Insmed at this important stage in its
development. I believe ARIKAYCE has the potential to have a
positive impact on patients’ lives and I believe Insmed has the
potential to continue to develop new treatments for patients with
serious rare diseases. I look forward to working with my fellow
Insmed Board members and the management team to help the Company
achieve its strategic objectives.”
Ms. Potter serves as a Director of Liberty
Mutual Holding Company, Rite Aid, Everyday Health and Proteus
Digital Health, and as a Trustee of The University of Chicago. She
served on the Board of Medco Health Solutions from December 2007
until its acquisition by Express Scripts in April 2012, and
continued as a Director of Express Scripts until June 2012.
From 2000 to 2005 Ms. Potter was President of
Commercial Operations and Chief Operating Officer of
Genentech, where she also served as a member of the Executive
Committee. At Genentech Ms. Potter led the worldwide
commercialization of a robust portfolio, including Avastin™,
Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™ and
TNkase™. Prior to Genentech Ms. Potter was President of
Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S.
Cardiovascular and Metabolic business. Before Bristol-Myers Squibb,
Ms. Potter was with Merck & Co. for 14 years where she rose
from her initial position as a sales representative to become Vice
President of an $800 million U.S. pharmaceutical business unit. She
began her career as a sales representative for The Procter &
Gamble Company. Ms. Potter graduated from The University of
Chicago.
About Insmed
Insmed Incorporated is a biopharmaceutical
company dedicated to improving the lives of patients battling
serious lung diseases. Insmed is focused on the development and
commercialization of ARIKAYCETM, or liposomal amikacin for
inhalation, for at least two identified orphan patient populations:
patients with nontuberculous mycobacteria (NTM) lung infections and
cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung
infections. For more information, please visit
http://www.insmed.com.
Forward-looking statements
This release contains forward-looking
statements. Words, and variations of words, such as “intend,”
“expect,” “will,” “anticipate,” “believe,” “continue,” “propose”
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of clinical trials and clinical data, the anticipated
benefits of Insmed’s products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory
approvals, bring products to market and successfully commercialize
products constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such risks
and uncertainties include, without limitation, failure or delay of
European, Canadian, U.S. Food and Drug Administration and other
regulatory reviews and approvals, competitive developments
affecting the Company’s product candidates, delays in product
development or clinical trials or other studies, patent disputes
and other intellectual property developments relating to the
Company’s product candidates, unexpected regulatory actions, delays
or requests, the failure of clinical trials or other studies or
results of clinical trials or other studies that do not meet
expectations, the fact that subsequent analyses of clinical trial
or study data may lead to different (including less favorable)
interpretations of trial or study results or may identify important
implications of a trial or study that are not reflected in
Company’s prior disclosures, and the fact that trial or study
results or subsequent analyses may be subject to differing
interpretations by regulatory agencies, the inability to
successfully develop the Company’s product candidates or receive
necessary regulatory approvals, the inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company’s financing requirements or
ability to raise additional capital, and other risks and challenges
detailed in the Company’s filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K
for the year ended December 31, 2013 and its subsequent
quarterly reports on Form 10-Q. Investors are cautioned not to
place undue reliance on any forward-looking statements that speak
only as of the date of this news release. The Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in its expectations.
Investor Relations
Contacts:LHAAnne Marie Fields, Senior Vice
President212-838-3777afields@lhai.comorBruce Voss, Managing
Director310-691-7100bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024